Chesapeake Asset Management
DFTX icon

Chesapeake Asset Management’s Definium Therapeutics DFTX Stock Holding History

Chesapeake Asset Management’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$10K Buy
262
+229
+694% +$9.6K 0.01% 255
2026
Q2 		$1.55K Hold
33
– – ﹤0.01% 348
2026
Q1 		$623 Hold
33
– – ﹤0.01% 317
2025
Q4 		$441 Hold
33
– – ﹤0.01% 343
2025
Q3 		$389 Hold
33
– – ﹤0.01% 305
2025
Q2 		$214 Hold
33
– – ﹤0.01% 312
2025
Q1 		$193 Hold
33
– – ﹤0.01% 520
2024
Q4 		$229 Hold
33
– – ﹤0.01% 479
2024
Q3 		$187 Hold
33
– – ﹤0.01% 493
2024
Q2 		$237 Hold
33
– – ﹤0.01% 323
2024
Q1 		$310 Hold
33
– – ﹤0.01% 305
2023
Q4 		$120 Hold
33
– – ﹤0.01% 371
2023
Q3 		$103 Hold
33
– – ﹤0.01% 421
2023
Q2 		$117 Hold
33
– – ﹤0.01% 409
2023
Q1 		$104 Buy
+33
New +$110 ﹤0.01% 406

Other funds holding DFTX

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $483B AUM 27.72% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $33.4B AUM 56.97% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Chesapeake Asset Management's DFTX Position: Q3 2026 in Review

Chesapeake Asset Management increased its Definium Therapeutics (DFTX) stake by 694% in Q3 2026, buying an estimated $9.6K and bringing the position to 262 shares worth $10K. The position accounts for 0.01% of the portfolio, ranked #255.

Chesapeake Asset Management first reported a position in DFTX in Q1 2023 and has held it in 15 quarters since. 253 funds tracked by Wall St. Rank hold DFTX as of Q3 2026.

  • Chesapeake Asset Management held 262 shares of Definium Therapeutics worth $10K as of Q3 2026.
  • Chesapeake Asset Management bought 229 Definium Therapeutics shares in Q3 2026, an estimated $9.6K.
  • Definium Therapeutics made up 0.01% of Chesapeake Asset Management's portfolio in Q3 2026, its #255 holding.
  • Chesapeake Asset Management first reported a position in Definium Therapeutics in Q1 2023 and has held it in 15 quarters since.
  • 253 funds tracked by Wall St. Rank held Definium Therapeutics as of Q3 2026.

Based on Chesapeake Asset Management's 13F filing for Q3 2026, filed 12 Nov 2026.